Adverse drug events (ADEs) are a major safety issue in clinical trials. Thus, predicting ADEs is key to developing safer medications and enhancing patient outcomes. To support this effort, we introduce CT-ADE, a dataset for multilabel ADE prediction in monopharmacy treatments. CT-ADE encompasses 2,497 drugs and 168,984 drug-ADE pairs from clinical trial results, annotated using the MedDRA ontology. Unlike existing resources, CT-ADE integrates treatment and target population data, enabling comparative analyses under varying conditions, such as dosage, administration route, and demographics. In addition, CT-ADE systematically collects all ADEs in the study population, including positive and negative cases. To provide a baseline for ADE prediction performance using the CT-ADE dataset, we conducted analyses using large language models (LLMs). The best LLM achieved an F1-score of 56%, with models incorporating treatment and patient information outperforming by 21%-38% those relying solely on the chemical structure. These findings underscore the importance of contextual information in ADE prediction and establish CT-ADE as a robust resource for safety risk assessment in pharmaceutical research and development.
View on arXiv@article{yazdani2025_2404.12827,
title={ An Evaluation Benchmark for Adverse Drug Event Prediction from Clinical Trial Results },
author={ Anthony Yazdani and Alban Bornet and Philipp Khlebnikov and Boya Zhang and Hossein Rouhizadeh and Poorya Amini and Douglas Teodoro },
journal={arXiv preprint arXiv:2404.12827},
year={ 2025 }
}